Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Marimed (MRMD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $24.4 million.

  • Marimed's Cost of Revenue rose 246.92% to $24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.1 million, marking a year-over-year increase of 741.83%. This contributed to the annual value of $95.1 million for FY2024, which is 1501.83% up from last year.
  • Per Marimed's latest filing, its Cost of Revenue stood at $24.4 million for Q3 2025, which was up 246.92% from $23.6 million recorded in Q2 2025.
  • In the past 5 years, Marimed's Cost of Revenue registered a high of $26.3 million during Q4 2024, and its lowest value of $11.5 million during Q1 2021.
  • For the 5-year period, Marimed's Cost of Revenue averaged around $19.7 million, with its median value being $20.1 million (2023).
  • Per our database at Business Quant, Marimed's Cost of Revenue skyrocketed by 34100.72% in 2021 and then rose by 21.25% in 2025.
  • Marimed's Cost of Revenue (Quarter) stood at $15.6 million in 2021, then grew by 28.7% to $20.0 million in 2022, then grew by 7.81% to $21.6 million in 2023, then increased by 21.83% to $26.3 million in 2024, then fell by 7.2% to $24.4 million in 2025.
  • Its Cost of Revenue stands at $24.4 million for Q3 2025, versus $23.6 million for Q2 2025 and $22.8 million for Q1 2025.